Spinraza’s new patient starts and regimen compliance may have declined in the United States in the second quarter, particularly among adults due to COVID-19 as it is administered in a physician's office.In July, Biogen completed the submission of the biologics license application (BLA) to the FDA, seeking approval of aducanumab for Alzheimer’s disease.